OnTarget Chemistry AB provides chemistry, preclinical, autoradiography, and bioanalytical services. Its chemistry services include medicinal chemistry, synthesis of reference compounds, and non-GMP scale-up synthesis; labelling with 2H, 3H, 14C, and more for use as internal standards and tools for both in vivo and in vitro studies; screening of crystallization conditions, with different salts and solvents; and route scouting, optimization of reaction conditions, and critical process parameters. The company’s preclinical services include MTS solubility in various buffers, protein binding studies, stability studies in plasma and whole blood, development and synthesis of derivatization agent to improve analyte quantification, metabolic profiling using primary hepatocytes/microsomes, non GXP bioanalysis, autoradiography and mass balance studies, and formulation development for IV/IP/SC administration. Its bioanaytical services include method development for partners; bioanalytical services for qualitative and quantitative drug, metabolite, and biomarker analysis; support for pre-clinical studies; bioanalytical support for clinical dose escalation studies (SAD and MAD) with short turnaround times and small sample volumes; dosing solution analysis for GLP studies; synthesis of internal standards, either stable isotope-labeled or suitable analogue; automated 96-well sample processing and analysis; and technology with automated and analytical instrumentation. It serves its customers in the United States, China, and internationally. OnTarget Chemistry AB was formerly known as Onco Targeting AB. The company was founded in 2008 and is based in Uppsala, Sweden. As of June 15, 2015, OnTarget Chemistry AB operates as a subsidiary of Recipharm AB (publ).